OrthoMedex LLC Announces Issuance of USPTO Patent # 10,117,973

“Methods of Using Water-Soluble Inorganic Compounds for Implants”

Bioactive Orthopedic Implants

On OrthoMedex’s 3rd year anniversary, it is pleased to announce the issuance of its 3rd USPTO Patent # 10,117,973, entitled: Methods of Using Water-Soluble Inorganic Compounds for Implants. This continuation patent compliments a suite of prior, and pending USPTO patents relating to the use of water-soluble inorganic compounds, such as bioactive glass, to render orthopedic and dental implants ‘bioactive’. The osteostimulative regenerative bone tissue attributes of bioactive glass facilitate enhanced implant osseointegration. The technology is also capable of providing the implant with broad-spectrum antimicrobial prophylaxis. OrthoMedex’s suite of intellectual property has broad application in the fields of orthopedic trauma, orthobiologics, reconstruction and revision, and spinal surgery, as well as dental implantology.

Orthopedic hip and knee revision surgery alone costs US healthcare $4.7B annually. Arthroplasty revision surgery within 90-days of hospital discharge is no longer reimbursable under the CMS Comprehensive Care for Joint Replacement [CJR] ‘bundled’ payment policy. Many orthopedic infections are no longer reimbursable under the CMS ‘Hospital- Acquired Conditions’ rubric. Healthcare outcomes, re patient morbidity and mortality, are also adversely affected by orthopedic revision surgery.

“By integrating the osseostimulative attributes of bioactive glass with implantable biomaterials, one can fabricate orthopedic implants that are truly ‘bioactive’. Such implants facilitate bone growth and implant osseointegration, rendering aseptic implant loosening and consequently revision surgery less likely,” said Jim Walls, OrthoMedex’s Founder & CEO. “Regardless of the nature of the orthopedic surgery, enhanced implant fixation and antimicrobial implant prophylaxis will reduce the likelihood of otherwise avoidable revision surgeries, driving down overall healthcare costs and safeguarding the hospital’s P&L from having to absorb unreimbursed CMS treatment costs. It is also obviously better for the patient.”

The company was recently the recipient of a $1.4MM Medical Valley EMN e.V. Internationalization Collaboration grant funded by Germany’s Ministry of Education and Research [BMBF], to investigate various implant applications for the technology. International collaborators include the Fraunhofer
Institute’s Translational Center for Regenerative Therapies, Friedrich-Alexander University, and the University of Connecticut Health Center.

For further information please contact:

Jim Walls  
Founder & CEO  
Email: jim.walls@orthomedex.com  
Mobile: +1.203.859.2997

Or Visit:  
www.orthomedex.com